Berwyn, PA – February 12, 2020 – CuRAGE Therapeutics announced today that its lead drug candidate CR-3, a monoclonal antibody that binds to RAGE (receptor for advanced glycation endproducts), exhibited an additional positive effect in restoring blood flow in a pig model of dia...